Original InvestigationPredicting Persistent Left Ventricular Dysfunction Following Myocardial Infarction: The PREDICTS Study
Under an Elsevier user license
open archive
Key Words
heart failure
remodeling
risk assessment
ventricular ejection fraction
Abbreviations and Acronyms
ACEI
angiotensin-converting enzyme inhibitor
ARB
angiotensin receptor blocker
BNP
B-type natriuretic peptide
CABG
coronary artery bypass graft
CI
confidence interval
EF
ejection fraction
HF
heart failure
ICD
implantable cardioverter-defibrillator
LV
left ventricular
MI
myocardial infarction
OR
odds ratio
PCI
percutaneous coronary intervention
ULN
upper limit of normal
VF
ventricular fibrillation
Cited by (0)
The study was supported by grants from the National Institutes of Health/National Heart, Lung, and Blood Institute (NIH/NHLBI) to Dr. Olgin (U01-HL089458) and Dr. Pletcher (U01-HL089145), as well as from Medtronic and ZOLL Medical Corporation. Dr. Morin has served on the speakers bureau for Medtronic Inc., Biotronik, and Zoll; and has received research grant support from Medtronic and Boston Scientific. Dr. Zweibel has served as a consultant for and speaker for Medtronic Inc. Dr. Buxton has received research grant support from Medtronic and Biosense-Webster. Dr. Olgin has received grant support from Zoll and Medtronic. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.